Explain this page
Arphra AIPlain-English read on BioAge Labs, Inc.’s valuation06-16today
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk6d
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk6d
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk6d
- BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript14d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $42.20 (+96.55%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.37% | +4.78% | +29.26% | +11.24% | +58.10% | +62.28% | +394.70% | +17.26% | +17.26% | +17.26% | +17.26% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$19.77
357 sh
Bid
$19.49
2 sh
Ask
$21.95
2 sh
Spread
$2.460
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Real Estate+1.28%
- Industrials+1.01%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.03%
- Utilities-0.09%
- Financial Services-0.18%
- Communication Services-0.56%
- Technology-0.77%
- Consumer Cyclical-0.83%
- Consumer Defensive-0.98%
Top industries (issuer's industry highlighted)
- Biotechnology+7.27%
- Software - Services-5.92%
- Electronic Gaming & Multimedia-3.76%
- Financial - Mortgages-3.51%
- Software - Infrastructure-3.12%
- Electrical Equipment & Parts+2.70%
- Staffing & Employment Services-2.69%
- Apparel - Footwear & Accessories-2.61%
- Coal-2.36%
- Advertising Agencies+2.35%
- Engineering & Construction+2.33%
- Broadcasting-2.30%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Riskglobenewswire.com·Jun 16, 2026
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Riskglobenewswire.com·Jun 16, 2026
- BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Riskglobenewswire.com·Jun 16, 2026
- BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 08, 2026
- BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Diseasemarketbeat.com·Jun 06, 2026
- BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcriptseekingalpha.com·May 08, 2026
- BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trialsmarketbeat.com·May 08, 2026
- BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.com·May 08, 2026
Peers
No peer list available for BIOA.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|